Table 1. Participant characteristics.

		Intervention group (n = 104)		Control group (N = 104)
		N	%	N	%	X2	p
Residence						4,636	0,326
	Nicosia	42	40,4%	35	33,7%
	Limassol	16	15,4%	17	16,3%
	Paphos	30	28,8%	24	23,1%
	Larnaka	14	13,5%	25	24,0%
	Ammochostos	2	1,9%	3	2,9%
Gender						—	—
	Male	52	50,0%	52	50,0%
	Female	52	50,0%	52	50,0%
Age						3,273	0,351
	31–40	7	6,7%	14	13,5%
	41–50	30	28,8%	25	24,0%
	51–60	43	41,3%	38	36,5%
	>60	24	23,1%	27	26,0%
Diagnoses						1,075	0,584
	T3a, Gleason score 8	41	39,4%	45	43,3%
	T3b, Gleason score 9	11	10,6%	7	6,7%
	T3N1M0 (Breast Cancer)	52	50,0%	52	50,0%
Type of Cancer						—	—
	Breast cancer	52	50,0%	52	50,0%
	Prostate cancer	52	50,0%	52	50,0%
Type of treatment			0,0%		0,0%
Breast Cancer						0,388	0,533
	Surgery, Adjuvant chemotherapya	16	30,8%	19	36,5%
	Surgery, Adjuvant chemotherapya, radiation	36	69,2%	33	63,5%
Prostate Cancer						0,769	0,8568
	Surgery (Radical Prostatectomy)	2	3,8%	2	3,8%
	Surgery, Radiotherapy	7	13,5%	5	9,6%
	Radiation, androgen deprivation therapy (ADT)	11	21,2%	9	17,3%
	Androgen deprivation therapy (ADT), Adjuvant chemotherapyb	32	61,5%	36	69,2%
Level of education						3,475	0,481
	No formal education	10	9,6%	14	13,5%
	Primary school	16	15,4%	9	8,7%
	Secondary school	25	24,0%	30	28,8%
	Higher education (college/polytechnic)	27	26,0%	23	22,1%
	University degree	26	25,0%	28	26,9%

a Doxorubicin 60 mg/m 2 IV plus cyclophosphamide 600 mg/m 2 IV on day 1 every 21 days for four cycles followed by Docetaxel 100mg/m2 IV. Repeat cycle every 21 days for 4 cycles.

b Docetaxel dosed at 75 mg/m2 every 3 weeks + Prednisone 10mg.